1505 related articles for article (PubMed ID: 27840009)
21. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT.
Pekmezci M; Rice T; Molinaro AM; Walsh KM; Decker PA; Hansen H; Sicotte H; Kollmeyer TM; McCoy LS; Sarkar G; Perry A; Giannini C; Tihan T; Berger MS; Wiemels JL; Bracci PM; Eckel-Passow JE; Lachance DH; Clarke J; Taylor JW; Luks T; Wiencke JK; Jenkins RB; Wrensch MR
Acta Neuropathol; 2017 Jun; 133(6):1001-1016. PubMed ID: 28255664
[TBL] [Abstract][Full Text] [Related]
22. An autophagic gene-based signature to predict the survival of patients with low-grade gliomas.
Chen J; Li Y; Han X; Pan Y; Qian X
Cancer Med; 2021 Mar; 10(5):1848-1859. PubMed ID: 33591634
[TBL] [Abstract][Full Text] [Related]
23. Combined IDH1 mutation and MGMT methylation status on long-term survival of patients with cerebral low-grade glioma.
Tanaka K; Sasayama T; Mizukawa K; Takata K; Sulaiman NS; Nishihara M; Kohta M; Sasaki R; Hirose T; Itoh T; Kohmura E
Clin Neurol Neurosurg; 2015 Nov; 138():37-44. PubMed ID: 26276726
[TBL] [Abstract][Full Text] [Related]
24. Combination genetic signature stratifies lower-grade gliomas better than histological grade.
Chan AK; Yao Y; Zhang Z; Shi Z; Chen L; Chung NY; Liu JS; Li KK; Chan DT; Poon WS; Wang Y; Zhou L; Ng HK
Oncotarget; 2015 Aug; 6(25):20885-901. PubMed ID: 26369702
[TBL] [Abstract][Full Text] [Related]
25. Increased intratumoral infiltration in IDH wild-type lower-grade gliomas observed with diffusion tensor imaging.
Aliotta E; Batchala PP; Schiff D; Lopes BM; Druzgal JT; Mukherjee S; Patel SH
J Neurooncol; 2019 Nov; 145(2):257-263. PubMed ID: 31531788
[TBL] [Abstract][Full Text] [Related]
26. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
[TBL] [Abstract][Full Text] [Related]
27. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560
[TBL] [Abstract][Full Text] [Related]
29. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.
Zhang ZY; Chan AK; Ding XJ; Qin ZY; Hong CS; Chen LC; Zhang X; Zhao FP; Wang Y; Wang Y; Zhou LF; Zhuang Z; Ng HK; Yan H; Yao Y; Mao Y
Oncotarget; 2015 Sep; 6(28):24871-83. PubMed ID: 26314843
[TBL] [Abstract][Full Text] [Related]
30. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.
Wiestler B; Capper D; Holland-Letz T; Korshunov A; von Deimling A; Pfister SM; Platten M; Weller M; Wick W
Acta Neuropathol; 2013 Sep; 126(3):443-51. PubMed ID: 23904111
[TBL] [Abstract][Full Text] [Related]
31. Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome.
Kiviniemi A; Gardberg M; Kivinen K; Posti JP; Vuorinen V; Sipilä J; Rahi M; Sankinen M; Minn H
Oncotarget; 2017 Jul; 8(30):49123-49132. PubMed ID: 28467778
[TBL] [Abstract][Full Text] [Related]
32. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
33. Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
Li MY; Wang YY; Cai JQ; Zhang CB; Wang KY; Cheng W; Liu YW; Zhang W; Jiang T
PLoS One; 2015; 10(6):e0130872. PubMed ID: 26115094
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Value of Immune-Related lncRNA SBF2-AS1 in Diffuse Lower-Grade Glioma.
Zhang Q; Liu XJ; Li Y; Ying XW; Chen L
Technol Cancer Res Treat; 2021; 20():15330338211011966. PubMed ID: 34159865
[TBL] [Abstract][Full Text] [Related]
35. MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status.
Li G; Wang Z; Zhang C; Liu X; Yang F; Sun L; Liang J; Hu H; Liu Y; You G; Bao Z; Zhang W; Wang Z; Jiang T
Dis Markers; 2018; 2018():5975216. PubMed ID: 29887919
[TBL] [Abstract][Full Text] [Related]
36. Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups.
Juratli TA; Tummala SS; Riedl A; Daubner D; Hennig S; Penson T; Zolal A; Thiede C; Schackert G; Krex D; Miller JJ; Cahill DP
J Neurooncol; 2019 Jan; 141(2):327-335. PubMed ID: 30536195
[TBL] [Abstract][Full Text] [Related]
37. DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development.
Binder H; Willscher E; Loeffler-Wirth H; Hopp L; Jones DTW; Pfister SM; Kreuz M; Gramatzki D; Fortenbacher E; Hentschel B; Tatagiba M; Herrlinger U; Vatter H; Matschke J; Westphal M; Krex D; Schackert G; Tonn JC; Schlegel U; Steiger HJ; Wick W; Weber RG; Weller M; Loeffler M
Acta Neuropathol Commun; 2019 Apr; 7(1):59. PubMed ID: 31023364
[TBL] [Abstract][Full Text] [Related]
38. Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011-2017): a multicenter retrospective study from CGGA.
Zhang K; Liu X; Li G; Chang X; Li S; Chen J; Zhao Z; Wang J; Jiang T; Chai R
Cancer Biol Med; 2022 Nov; 19(10):1460-76. PubMed ID: 36350010
[TBL] [Abstract][Full Text] [Related]
39. Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma.
Maimaiti A; Wang X; Pei Y; Nuermaimaiti N; Tuersunniyazi A; Abula Y; Feng Z; Jiang L; Shi X; Kasimu M
Aging (Albany NY); 2021 Jun; 13(11):15164-15192. PubMed ID: 34081618
[TBL] [Abstract][Full Text] [Related]
40. RIPK3 is a novel prognostic marker for lower grade glioma and further enriches IDH mutational status subgrouping.
Vergara GA; Eugenio GC; Malheiros SMF; Victor EDS; Weinlich R
J Neurooncol; 2020 May; 147(3):587-594. PubMed ID: 32222932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]